Search
-
New#NewAseBioMember | “AseBio constitutes a meeting point and driving force for the main acto...
Meet Lifesome Therapeutics, our new member. We talked its Diego Pazos Castro, Cancer & Microbiology Research Scientist.
-
NewThe European authority HERA visits HIPRA for its productive capacity in the face of future...
The top leadership team from HERA (Health Emergency Preparedness and Response), the European Commission's authority for the prevention, detection and rapid response to health emergencies in the
-
NewJuan Basterra (Mikrobiomik) | "In the last 10 years, decisive steps have been taken to und...
Mikrobiomik is working to become the first company globally to market the first biological drug based on gut microbiota in the European Union for the indication of recurrence of 'Clostridium difficile
-
NewOryzon announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb ...
Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre.
-
NewAseBio and the Ministry of Health analyze the challenges and opportunities of Artificial I...
The event "Challenges and Opportunities for Spain in the Application of AI in Health Data Spaces," organized by AseBio together with the Ministry of Health, brought together leading organizations from
-
NewOvercoming Challenges in the Current Biotech Landscape
Biotech entrepreneurs have experienced a demanding drug development environment in the last 24 months. To succeed, biotech leaders must overcome challenges associated with planning, fundraising, and
-
NewAlira Health Publishes a White Paper on the Impact of New European Union Regulations on Ad...
It provides an overview of the key changes that will impact access to innovative medicines and advanced therapies in the EU.
-
New#NewAseBioMember | “AseBio gives us access to key resources, and potential collaborations ...
Meet ASPARIA GLYCOMICS, our new member. We talked to its Ane Rodrigo, Sales & Marketing Manager.
-
NewORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus ...
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity. A third cohort is ongoing following FDA’s OPTIMUS
-
New#NewAseBioMember | “AseBio represents an essential platform for collaboration, networking ...
Meet Paralab Bio, our new member. We talked to its Andrea Zapater, Bio Product Specialist.
-
NewInvestment in R&D by biotech companies grows by 17% to 1,218 million euros
Private funding raised by the sector reached an all-time high, surpassing 228 million euros after a 37% increase.
-
NewBiotechnology and bio-manufacturing win 350 million euros in support and investment from E...
The European Commission thus reinforces biotechnology as central to Europe's green, digital and long-term industrial transition.
-
NewRafael Simó: "We should talk about "obesities" instead of "obesity" because more and more...
Geneis Biomed interviews Dr. Rafael Simón, head of the Endocrinology and Nutrition Department at Vall d'Hebron University Hospital and Director of the Diabetes and Metabolism Research Unit at Vall d
-
NewBiotechnology: key to addressing the triple environmental crisis and achieving the Sustain...
Biotechnology addresses environmental challenges through bioremediation, the production of renewable energy, sustainable agriculture, or the reduction of greenhouse gas emissions.
-
NewRegister for Webinar: Oligonucleotide Drugs: Key ADME & DMPK Insights
Pharmaron is holding a training webinar on June 20 on the importance of oligonucleotide drugs in modern medicine.
-
NewUse of biotechnology in advanced therapies and new technologies in the spanish market
Among the most important emerging technologies are the manipulation of the microbiota, CAR-T cell therapies, and gene editing using CRISPR-Cas9, techniques that are positioning Spain as a benchmark in
-
NewVIVEbiotech receives the “New Company of Gipuzkoa 2024” award from ADEGI
The award recognizes the success of companies less than 10 years old that create wealth and employment in the Basque Country community.
-
NewOryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ...
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML). The combination showed substantial
-
NewOryzon to provide corporate progress updates at several events in June
BIO International Convention 2024. Congreso de la European Hematology Association (EHA) 2024. European Network to Cure ALS (ENCALS) 2024.
-
NewBCN HEALTH publishes a study estimating the cost of thalassaemia care across the world
BCN HEALTH desarrolló un modelo de costes aplicable a nivel mundial para la atención de la talasemia.
-
NewOryzon selected as Associated Partner in the first Important Project of Common European In...
Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain . Oryzon to validate epigenetic agents by applying a personalized